Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells.

Montanari M, Carbone MR, Coppola L, Giuliano M, Arpino G, Lauria R, Nardone A, Leccia F, Trivedi MV, Garbi C, Bianco R, Avvedimento EV, De Placido S, Veneziani BM.

Mol Cancer Res. 2018 Sep 21. doi: 10.1158/1541-7786.MCR-17-0324. [Epub ahead of print]

PMID:
30242055
2.

GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.

Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfard S, Al-Rawi A, Yadav V, Qin L, Nanda S, Sethunath V, Fu X, De Angelis C, Narkar VA, Osborne CK, Schiff R, Trivedi MV.

Breast Cancer Res Treat. 2018 Jul;170(2):279-292. doi: 10.1007/s10549-018-4751-9. Epub 2018 Mar 24.

PMID:
29574636
3.

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize.

Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, Schiff R, Trivedi MV.

Cancer Res. 2018 Feb 15;78(4):845-852. doi: 10.1158/0008-5472.CAN-17-2748. Epub 2018 Feb 2.

PMID:
29437766
4.

Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?

Ekinci E, Nathoo S, Korattyil T, Vadhariya A, Zaghloul HA, Niravath PA, Abughosh SM, Trivedi MV.

J Cancer Surviv. 2018 Jun;12(3):348-356. doi: 10.1007/s11764-017-0674-4. Epub 2018 Feb 2. Review.

PMID:
29396760
5.

PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?

Schettini F, Buono G, Trivedi MV, De Placido S, Arpino G, Giuliano M.

Breast Care (Basel). 2017 Oct;12(5):290-294. doi: 10.1159/000481657. Epub 2017 Oct 19. Review.

6.

Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy.

Niravath P, Bhat R, Al-Ameri M, AlRawi A, Foreman C, Trivedi MV.

Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.330.

7.

Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

Hwang GS, Bhat R, Crutchley RD, Trivedi MV.

Pharmacogenomics J. 2018 Apr;18(2):201-208. doi: 10.1038/tpj.2017.36. Epub 2017 Aug 1. Review.

PMID:
28762370
8.

A rare and unusual case report of Langerhans cell histiocytosis.

Rao DG, Trivedi MV, Havale R, Shrutha SP.

J Oral Maxillofac Pathol. 2017 Jan-Apr;21(1):140-144. doi: 10.4103/jomfp.JOMFP_10_17.

9.

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6600-E6609. Epub 2016 Oct 6.

10.

New fluoride MI Varnish as root canal sealer: An in vitro analysis of bacterial leakage.

Rao DG, Trivedi MV, Havale R, Shrutha SP.

J Indian Soc Pedod Prev Dent. 2016 Oct-Dec;34(4):359-63. doi: 10.4103/0970-4388.191418.

11.

Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.

Sulaica E, Han T, Wang W, Bhat R, Trivedi MV, Niravath P.

Breast Cancer Res Treat. 2016 Jun;157(2):203-210. doi: 10.1007/s10549-016-3827-7. Epub 2016 May 13. Review.

PMID:
27178335
12.

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R.

Mol Cancer Res. 2016 May;14(5):470-81. doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10.

13.

Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review.

Sayles C, Hickerson SC, Bhat RR, Hall J, Garey KW, Trivedi MV.

Nutr Clin Pract. 2016 Apr;31(2):171-9. doi: 10.1177/0884533615611857. Epub 2015 Oct 27. Review.

PMID:
26507188
14.

The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.

Do T, Medhekar R, Bhat R, Chen H, Niravath P, Trivedi MV.

Breast Cancer Res Treat. 2015 Oct;153(3):591-7. doi: 10.1007/s10549-015-3531-z. Epub 2015 Sep 4. Review.

PMID:
26337685
15.

The changing role of ER in endocrine resistance.

Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R.

Breast. 2015 Nov;24 Suppl 2:S60-6. doi: 10.1016/j.breast.2015.07.015. Epub 2015 Aug 10. Review.

16.

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26.

17.

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.

Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV.

Breast Cancer Res. 2015 Jan 9;17:3. doi: 10.1186/s13058-014-0508-5.

18.
19.

Metastasis dormancy in estrogen receptor-positive breast cancer.

Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK.

Clin Cancer Res. 2013 Dec 1;19(23):6389-97. doi: 10.1158/1078-0432.CCR-13-0838. Review.

20.
21.

Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases.

Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1265-71. doi: 10.1007/s00280-013-2302-y. Epub 2013 Oct 8.

PMID:
24101145
22.

Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.

Parma J, Pavlick A, Schiff R, Osborne CK, Chang JC, Rimawi M, Trivedi MV.

Pharmacotherapy. 2013 Oct;33(10):1126-9. doi: 10.1002/phar.1308. Epub 2013 Jun 6.

PMID:
23744830
23.

Die and let live: harnessing BikDD to combat breast cancer stem cells.

Giuliano M, Trivedi MV, Schiff R.

Breast Cancer Res. 2012 May 23;14(3):310.

24.

Eribulin: a novel cytotoxic chemotherapy agent.

Preston JN, Trivedi MV.

Ann Pharmacother. 2012 Jun;46(6):802-11. doi: 10.1345/aph.1Q636. Epub 2012 May 22. Review.

PMID:
22619477
25.

Denosumab for treatment of breast cancer bone metastases and beyond.

Nangia JR, Ma JD, Nguyen CM, Mendes MA, Trivedi MV.

Expert Opin Biol Ther. 2012 Apr;12(4):491-501. doi: 10.1517/14712598.2012.664634. Epub 2012 Feb 21. Review.

PMID:
22348344
26.

Biological mechanisms and clinical implications of endocrine resistance in breast cancer.

Giuliano M, Schifp R, Osborne CK, Trivedi MV.

Breast. 2011 Oct;20 Suppl 3:S42-9. doi: 10.1016/S0960-9776(11)70293-4. Review.

PMID:
22015292
27.

The role of thiols and disulfides on protein stability.

Trivedi MV, Laurence JS, Siahaan TJ.

Curr Protein Pept Sci. 2009 Dec;10(6):614-25. Review.

Supplemental Content

Loading ...
Support Center